A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

Medication is not a quick fix for obesity, Dr. Samuel L. Wilcox said during a "Lunch & Learn" session at the Iola Public ...

An injectable weight-loss treatment is now available through primary care across the UK - and general practices across ...

GLP-1 drugs like semaglutide and tirzepatide show promise in treating obesity, with benefits including weight loss and ...

GP in many parts of England are having explain to eligible patients that tirzepatide (Mounjaro) cannot be prescribed in ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug on the market.

People seeking weight-loss medication on the NHS are being warned it is not yet available in Derbyshire and only a very ...